Abnormal CD40 ligand (CD154) expression in human immunodeficiency virus-infected children

M R O'Gorman1, B DuChateau, M Paniagua

  • 1Children's Memorial Hospital and the Northwestern University Medical School, Chicago, Illinois 60614-3394, USA. mogorman@nwu.edu

Insights

Pediatric HIV infection impairs T helper cell CD154 expression, affecting immune responses. This CD40 ligand deficiency correlates with immunodeficiency but not viral load in children.

Area of Science:

  • Immunology
  • Virology
  • Pediatrics

Background:

  • CD40 ligand (CD154) is crucial for B-cell function and immunoglobulin class switching.
  • Pediatric HIV infection is characterized by early B-cell abnormalities and immune dysregulation.
  • CD154 expression on T helper cells plays a key role in adaptive immunity.

Purpose of the Study:

  • To investigate CD154 expression levels on T helper cells in HIV-infected children.
  • To compare CD154 expression in HIV-infected children with uninfected controls.
  • To determine the correlation between CD154 expression and clinical parameters in pediatric HIV infection.

Main Methods:

  • Flow cytometry was used to measure CD154 expression on T helper cells (CD3(+) CD8(-)).
  • Measurements were taken on resting and in vitro-activated T helper cells.
  • Correlations were analyzed between CD154 levels, CD4 T-cell counts, viral load, and immunoglobulin concentrations.

Main Results:

  • HIV-infected children showed significantly lower percentages and mean fluorescence channel (MFC) of activated CD154+ T helper cells compared to controls.
  • CD154 expression on resting T helper cells did not differ significantly between groups.
  • Activated CD154 expression correlated with CD4 T-cell levels (r=0.707, P=0.003) and baseline immunoglobulin A levels in HIV-infected children.

Conclusions:

  • HIV-infected children exhibit impaired regulation of CD154 expression on activated T helper cells.
  • This CD154 deficiency may contribute to the immune dysregulation observed in pediatric HIV infection.
  • Further research is warranted to explore therapeutic strategies targeting CD154 in pediatric HIV.